TrialJournal of hematology & oncology2022

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease.

Ja Min Byun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.